Navigation Links
A Statement from Nova Oculus Concerning Clinical Trials for AMD in Canada
Date:3/14/2019

ON NOVEMBER 27, 2018, Nova Oculus Partners, LLC, issued a press release announcing that its Canadian partner, the Eye Machine Canada Inc., had been given approval to begin a clinical patient trial in Edmonton, Canada, using Nova Oculus’s pioneering technology for treating Age-Related Macular Degeneration (AMD).

The previous month, the medical devices bureau of Health Canada had granted an Investigational Testing Authorization for that trial. In making that announcement, the press release also reported that approval of the trial’s protocol and its investigator has been given by the clinical trials committee of the Health Research Ethics Board of Alberta (HREBA).

However, the press release’s assertion that approval of the protocol and the study’s investigator by the clinical trials committee was in error. It was the result of a misunderstanding based on a communication from HREBA that was assumed to be granting such approval. As of today’s date, the Eye Machine Canada Inc. is still awaiting the committee’s approval to proceed with the study.

Nova Oculus Partners, LLC, did not intend to suggest there was approval that at the time it did not believe had actually been granted. Moreover, upon learning of the actual status of the application, Nova Oculus made it clear in subsequent direct communications with its investors that the Eye Machine Canada is still awaiting approval from HREBA of its protocol.

Nova Oculus Partners, LLC, unreservedly apologizes to the members of HREBA, to its clinical trials committee, to the Eye Machine Canada Inc., and to the trial’s investigators for this misunderstanding.

Read the full story at https://www.prweb.com/releases/a_statement_from_nova_oculus_concerning_clinical_trials_for_amd_in_canada/prweb16165557.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology technology :

1. Biohaven Files Registration Statement for Proposed Public Offering of its Common Shares
2. BioAmber Issues Statement Required by Section 610(b) of the NYSE MKT Company Guide
3. ASBMT Official Statement Opposing Executive Order on Immigration
4. ASBM Statement on Final Guidance for Industry Nonproprietary Naming of Biological Products
5. Neurotrope Issues Statement On Eli Lillys Solanezumab
6. BIOREM Responds to Statement of Claim
7. Intrexon Expresses Support for Resident Commissioner of Puerto Ricos Statements on Combatting Aedes aegypti Mosquitoes in Puerto Rico and Other U.S. Jurisdictions
8. Lone Star Value Issues Statement To Fellow Enzo Shareholders
9. NW Bio Statement Regarding Appointments
10. NW Bio Issues Statement on Highly Unusual Trading Activity
11. Depomed Issues Statement on Horizon Pharma plcs Unsolicited Exchange Offer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2019)... Calif. (PRWEB) , ... August 27, 2019 , ... Dr. ... She recently opened North Peninsula Veterinary Surgical Group , a new surgical ... however there are plans to expand and add more veterinary specialists as the practice ...
(Date:8/23/2019)... ... August 22, 2019 , ... An ... and is scheduled to broadcast 4Q/2019. Check your local listings for more information. ... for generic drug delivery. Focusing on therapeutics for children and the elderly, viewers ...
(Date:8/8/2019)... ... August 08, 2019 , ... ... for sales and service organizations, today announced that the company’s Studio Intelligent Virtual ... the IVA market . Inference will officially accept the award at Frost & ...
(Date:8/6/2019)... Ill. (PRWEB) , ... August 05, 2019 , ... ... that Jason Casarella has been recognized as a distinguished leader by PharmaVOICE magazine, ... featured in an article in the magazine’s July/August special issue. , As the ...
Breaking Biology Technology:
(Date:9/17/2019)... CA (PRWEB) , ... September 17, 2019 , ... ... recently presented at the 27th Series of the Australia Society of Implant Dentistry ... Implant Surgeon’s Perspective,” was part of the Surgical Aspects of Modern Implant Dentistry ...
(Date:9/11/2019)... ... September 09, 2019 , ... Greenberg Traurig, LLP attorneys ... will speak at DeviceTalks Minnesota, Sept. 9-10, at the Hyatt Regency, Minneapolis. Greenberg ... Life Sciences & Medical Technology Group have been featured speakers at every DeviceTalks ...
(Date:9/8/2019)... ... 06, 2019 , ... The Board of Directors of Cardea ... respective companies to proceed with a proposed business combination. After the closing, ... series of products leveraging the CRISPR-Chip technology. The closing of the proposed ...
Breaking Biology News(10 mins):